EIKN (NASDAQ:EIKN) Lowered to Sell Rating by Wall Street Zen

EIKN (NASDAQ:EIKN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

A number of other equities research analysts have also weighed in on the stock. Morgan Stanley started coverage on shares of EIKN in a report on Monday, March 2nd. They issued an “overweight” rating and a $32.00 price objective for the company. Cantor Fitzgerald began coverage on shares of EIKN in a report on Monday, March 2nd. They set an “overweight” rating on the stock. Bank of America began coverage on shares of EIKN in a research report on Monday, March 2nd. They issued a “buy” rating and a $34.00 target price on the stock. Zacks Research raised shares of EIKN to a “hold” rating in a research note on Friday, February 27th. Finally, JPMorgan Chase & Co. initiated coverage on shares of EIKN in a research report on Monday, March 2nd. They set an “overweight” rating and a $29.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, EIKN presently has an average rating of “Moderate Buy” and an average price target of $25.60.

EIKN Stock Performance

Shares of EIKN opened at $9.90 on Friday. EIKN has a 1 year low of $9.46 and a 1 year high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.